Harnessing senolytics and PARP inhibition to expand the antitumor activity of CDK4/6 inhibitors in prostate cancer
Published: 5 February 2025| Version 1 | DOI: 10.17632/vvwy6ndv9g.1
Contributors:
Julian Brandariz, Description
Includes RNAseq data from prostate cancer models before and after treatment with the CDK4/6 inhibitor abemaciclib.
Files
Institutions
- Vall d'Hebron Institut d'Oncologia
Categories
Prostate Cancer, Abemaciclib, Gene Expression, Cellular Senescence